{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T15:02:52Z","timestamp":1793026972251,"version":"4.5.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,12,11]],"date-time":"2020-12-11T00:00:00Z","timestamp":1607644800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,12,11]],"date-time":"2020-12-11T00:00:00Z","timestamp":1607644800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1007\/s40121-020-00374-7","type":"journal-article","created":{"date-parts":[[2020,12,11]],"date-time":"2020-12-11T12:08:49Z","timestamp":1607688529000},"page":"15-25","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Orally Administered Amoxicillin\/Clavulanate: Current Role in Outpatient Therapy"],"prefix":"10.1007","volume":"10","author":[{"given":"Balaji","family":"Veeraraghavan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yamuna Devi","family":"Bakthavatchalam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rani Diana","family":"Sahni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,12,11]]},"reference":[{"issue":"Suppl 2","key":"374_CR1","doi-asserted-by":"publisher","first-page":"S109","DOI":"10.1016\/j.ijantimicag.2007.07.015","volume":"30","author":"AM Geddes","year":"2007","unstructured":"Geddes AM, Klugman KP, Rolinson GN. Introduction: historical perspective and development of amoxicillin\/clavulanate. Int J Antimicrob Agents. 2007;30(Suppl 2):S109\u201312.","journal-title":"Int J Antimicrob Agents"},{"issue":"Suppl 1","key":"374_CR2","doi-asserted-by":"publisher","first-page":"i3","DOI":"10.1093\/jac\/dkh050","volume":"53","author":"AR White","year":"2004","unstructured":"White AR, Kaye C, Poupard J, et al. Augmentin (amoxicillin\/clavulanate) in the treatment of community-acquired respiratory tract infection: a review of the continuing development of an innovative antimicrobial agent. J Antimicrob Chemother. 2004;53(Suppl 1):i3-20.","journal-title":"J Antimicrob Chemother"},{"issue":"8169","key":"374_CR3","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/S0140-6736(80)91118-6","volume":"1","author":"AP Ball","year":"1980","unstructured":"Ball AP, Geddes AM, Davey PG, Farrell ID, Brookes GR. Clavulanic acid and amoxycillin: a clinical, bacteriological, and pharmacological study. Lancet. 1980;1(8169):620\u20133.","journal-title":"Lancet"},{"issue":"3","key":"374_CR4","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1093\/clinids\/24.3.457","volume":"24","author":"RR MacGregor","year":"1997","unstructured":"MacGregor RR, Graziani AL. Oral administration of antibiotics: a rational alternative to the parenteral route. Clin Infect Dis. 1997;24(3):457\u201367.","journal-title":"Clin Infect Dis"},{"issue":"10","key":"374_CR5","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1136\/thx.49.10.999","volume":"49","author":"IM Gould","year":"1994","unstructured":"Gould IM, Harvey G, Golder D, et al. Penetration of amoxycillin\/clavulanic acid into bronchial mucosa with different dosing regimens. Thorax. 1994;49(10):999\u20131001.","journal-title":"Thorax"},{"issue":"1","key":"374_CR6","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1128\/AAC.00133-06","volume":"52","author":"S Kiem","year":"2008","unstructured":"Kiem S, Schentag JJ. Interpretation of antibiotic concentration ratios measured in epithelial lining fluid. Antimicrob Agents Chemother. 2008;52(1):24\u201336.","journal-title":"Antimicrob Agents Chemother"},{"key":"374_CR7","unstructured":"The United States Food and Drug Administration. Prescribing information for Augmnetin. GSK. 2006. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/050564s051lbl.pdf. Accessed 11 Sept 2020."},{"issue":"7","key":"374_CR8","doi-asserted-by":"publisher","first-page":"e00145","DOI":"10.1128\/AAC.00145-19","volume":"63","author":"K Abdelraouf","year":"2019","unstructured":"Abdelraouf K, Stainton SM, Nicolau DP. In vivo pharmacodynamic profile of ceftibuten-clavulanate combination against extended-spectrum-\u03b2-lactamase-producing enterobacteriaceae in the murine thigh infection model. Antimicrob Agents Chemother. 2019;63(7):e00145-e219.","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"374_CR9","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1128\/AAC.45.9.2436-2440.2001","volume":"45","author":"I Gustafsson","year":"2001","unstructured":"Gustafsson I, L\u00f6wdin E, Odenholt I, et al. Pharmacokinetic and pharmacodynamic parameters for antimicrobial effects of cefotaxime and amoxicillin in an in vitro kinetic model. Antimicrob Agents Chemother. 2001;45(9):2436\u201340.","journal-title":"Antimicrob Agents Chemother"},{"key":"374_CR10","unstructured":"European Committee on Antimicrobial Susceptibility Testing (EUCAST). Amoxicillin. Rationale for the EUCAST clinical breakpoints, version 1.0. 2010. https:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Rationale_documents\/Amoxicillin_rationale_Nov2010_v_1.0.pdf. Accessed 17 Sept 2020."},{"issue":"12","key":"374_CR11","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1007\/s10096-019-03679-9","volume":"38","author":"JWS Cattrall","year":"2019","unstructured":"Cattrall JWS, As\u00edn-Prieto E, Freeman J, et al. A pharmacokinetic-pharmacodynamic assessment of oral antibiotics for pyelonephritis. Eur J Clin Microbiol Infect Dis. 2019;38(12):2311\u201321.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"6","key":"374_CR12","first-page":"956","volume":"74","author":"DM Wong","year":"2006","unstructured":"Wong DM, Blumberg DA, Lowe LG. Guidelines for the use of antibiotics in acute upper respiratory tract infections. Am Fam Phys. 2006;74(6):956\u201366.","journal-title":"Am Fam Phys"},{"issue":"12","key":"374_CR13","doi-asserted-by":"publisher","first-page":"e0220265","DOI":"10.1371\/journal.pone.0220265","volume":"14","author":"IA Critchley","year":"2019","unstructured":"Critchley IA, Cotroneo N, Pucci MJ, et al. The burden of antimicrobial resistance among urinary tract isolates of Escherichia coli in the United States in 2017. PLoS One. 2019;14(12):e0220265.","journal-title":"PLoS One"},{"issue":"9","key":"374_CR14","doi-asserted-by":"publisher","first-page":"e00143","DOI":"10.1128\/JCM.00143-19","volume":"57","author":"HJ Ho","year":"2019","unstructured":"Ho HJ, Tan MX, Chen MI, et al. Interaction between antibiotic resistance, resistance genes, and treatment response for urinary tract infections in primary care. J Clin Microbiol. 2019;57(9):e00143-e219.","journal-title":"J Clin Microbiol"},{"issue":"1","key":"374_CR15","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s12866-016-0749-9","volume":"16","author":"S Guyomard-Rabenirina","year":"2016","unstructured":"Guyomard-Rabenirina S, Malespine J, Ducat C, et al. Temporal trends and risks factors for antimicrobial resistant Enterobacteriaceae urinary isolates from outpatients in Guadeloupe. BMC Microbiol. 2016;16(1):121.","journal-title":"BMC Microbiol"},{"key":"374_CR16","first-page":"e14660","volume":"148","author":"S Erb","year":"2018","unstructured":"Erb S, Frei R, Tschudin Sutter S, et al. Basic patient characteristics predict antimicrobial resistance in E.\u00a0coli from urinary tract specimens: a retrospective cohort analysis of 5246 urine samples. Swiss Med Wkly. 2018;148:e14660.","journal-title":"Swiss Med Wkly"},{"issue":"2","key":"374_CR17","first-page":"389","volume":"30","author":"S Sabir","year":"2014","unstructured":"Sabir S, Ahmad Anjum A, Ijaz T, et al. Isolation and antibiotic susceptibility of E.\u00a0coli from urinary tract infections in a tertiary care hospital. Pak J Med Sci. 2014;30(2):389\u201392.","journal-title":"Pak J Med Sci"},{"key":"374_CR18","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.2147\/TCRM.S178855","volume":"14","author":"MQ Alanazi","year":"2018","unstructured":"Alanazi MQ. An evaluation of community-acquired urinary tract infection and appropriateness of treatment in an emergency department in Saudi Arabia. Ther Clin Risk Manag. 2018;14:2363\u201373.","journal-title":"Ther Clin Risk Manag"},{"issue":"2","key":"374_CR19","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1017\/S0950268813000988","volume":"142","author":"CS Horner","year":"2014","unstructured":"Horner CS, Abberley N, Denton M, et al. Surveillance of antibiotic susceptibility of Enterobacteriaceae isolated from urine samples collected from community patients in a large metropolitan area, 2010\u20132012. Epidemiol Infect. 2014;142(2):399\u2013403.","journal-title":"Epidemiol Infect"},{"issue":"10","key":"374_CR20","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1007\/s10096-020-03947-z","volume":"39","author":"E De Lorenzis","year":"2020","unstructured":"De Lorenzis E, Alba AB, Cepeda M, et al. Bacterial spectrum and antibiotic resistance of urinary tract infections in patients treated for upper urinary tract calculi: a multicenter analysis. Eur J Clin Microbiol Infect Dis. 2020;39(10):1971\u201381.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"3","key":"374_CR21","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1093\/jac\/dky488","volume":"74","author":"C Pulcini","year":"2019","unstructured":"Pulcini C, Clerc-Urmes I, Attinsounon CA, et al. Antibiotic resistance of Enterobacteriaceae causing urinary tract infections in elderly patients living in the community and in the nursing home: a retrospective observational study. J Antimicrob Chemother. 2019;74(3):775\u201381.","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"374_CR22","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1128\/AAC.38.3.494","volume":"38","author":"PJ Wu","year":"1994","unstructured":"Wu PJ, Shannon K, Phillips I. Effect of hyperproduction of TEM-1 beta-lactamase on in vitro susceptibility of Escherichia coli to beta-lactam antibiotics. Antimicrob Agents Chemother. 1994;38(3):494\u20138.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"374_CR23","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1093\/fampra\/cms029","volume":"29","author":"BJ Knottnerus","year":"2012","unstructured":"Knottnerus BJ, Grigoryan L, Geerlings SE, et al. Comparative effectiveness of antibiotics for uncomplicated urinary tract infections: network meta-analysis of randomized trials. Fam Pract. 2012;29(6):659\u201370.","journal-title":"Fam Pract"},{"issue":"2","key":"374_CR24","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1093\/jac\/49.2.367","volume":"49","author":"V Leflon-Guibout","year":"2002","unstructured":"Leflon-Guibout V, Ternat G, Heym B, et al. Exposure to co-amoxiclav as a risk factor for co-amoxiclav-resistant Escherichia coli urinary tract infection. J Antimicrob Chemother. 2002;49(2):367\u201371.","journal-title":"J Antimicrob Chemother"},{"issue":"10","key":"374_CR25","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1016\/S1473-3099(18)30353-0","volume":"18","author":"KD Vihta","year":"2018","unstructured":"Vihta KD, Stoesser N, Llewelyn MJ, et al. Trends over time in Escherichia coli bloodstream infections, urinary tract infections, and antibiotic susceptibilities in Oxfordshire, UK, 1998\u20132016: a study of electronic health records. Lancet Infect Dis. 2018;18(10):1138\u201349.","journal-title":"Lancet Infect Dis"},{"issue":"10134","key":"374_CR26","first-page":"1966","volume":"391","author":"T Lancet","year":"2018","unstructured":"Lancet T. Balancing treatment with resistance in UTIs. Lancet. 2018;391(10134):1966.","journal-title":"Lancet"},{"issue":"1","key":"374_CR27","doi-asserted-by":"publisher","first-page":"e13792","DOI":"10.5812\/jjm.13792","volume":"8","author":"A Beytur","year":"2014","unstructured":"Beytur A, Yakupogullari Y, Oguz F, et al. Oral amoxicillin-clavulanic acid treatment in urinary tract infections caused by extended-spectrum beta-lactamase-producing organisms. Jundishapur J Microbiol. 2014;8(1):e13792.","journal-title":"Jundishapur J Microbiol"},{"issue":"Suppl 3","key":"374_CR28","first-page":"iii25","volume":"65","author":"A Pallett","year":"2010","unstructured":"Pallett A, Hand K. Complicated urinary tract infections: practical solutions for the treatment of multiresistant Gram-negative bacteria. J Antimicrob Chemother. 2010;65(Suppl 3):iii25-33.","journal-title":"J Antimicrob Chemother"},{"issue":"7","key":"374_CR29","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1164\/rccm.201908-1581ST","volume":"200","author":"JP Metlay","year":"2019","unstructured":"Metlay JP, Waterer GW, Long AC, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019;200(7):e45\u201367.","journal-title":"Am J Respir Crit Care Med"},{"issue":"8","key":"374_CR30","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1093\/jac\/dkv088","volume":"70","author":"M D\u00edez-Aguilar","year":"2015","unstructured":"D\u00edez-Aguilar M, Morosini MI, L\u00f3pez-Cerero L, et al. Performance of EUCAST and CLSI approaches for co-amoxiclav susceptibility testing conditions for clinical categorization of a collection of Escherichia coli isolates with characterized resistance phenotypes. J Antimicrob Chemother. 2015;70(8):2306\u201310.","journal-title":"J Antimicrob Chemother"},{"issue":"11","key":"374_CR31","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1093\/jac\/dkt218","volume":"68","author":"MA Leverstein-van Hall","year":"2013","unstructured":"Leverstein-van Hall MA, Waar K, Muilwijk J, et al. Consequences of switching from a fixed 2:1 ratio of amoxicillin\/clavulanate (CLSI) to a fixed concentration of clavulanate (EUCAST) for susceptibility testing of Escherichia coli. J Antimicrob Chemother. 2013;68(11):2636\u201340.","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"374_CR32","doi-asserted-by":"publisher","first-page":"e02026","DOI":"10.1128\/AAC.02026-19","volume":"64","author":"TJ Davies","year":"2020","unstructured":"Davies TJ, Stoesser N, Sheppard AE, et al. Reconciling the potentially irreconcilable? Genotypic and phenotypic amoxicillin-clavulanate resistance in Escherichia coli. Antimicrob Agents Chemother. 2020;64(6):e02026-e2119.","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"374_CR33","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1007\/s10096-018-3338-z","volume":"37","author":"J Cohen Stuart","year":"2018","unstructured":"Cohen Stuart J, Leverstein-Van Hall M, Kortmann W, et al. Ceftibuten plus amoxicillin-clavulanic acid for oral treatment of urinary tract infections with ESBL producing E.\u00a0coli and K. pneumoniae: a retrospective observational case-series. Eur J Clin Microbiol Infect Dis. 2018;37(10):2021\u20135.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"8","key":"374_CR34","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1089\/mdr.2019.0065","volume":"25","author":"M Al-Tamimi","year":"2019","unstructured":"Al-Tamimi M, Abu-Raideh J, Albalawi H, et al. Effective oral combination treatment for extended-spectrum beta-lactamase-producing Escherichia coli. Microb Drug Resist. 2019;25(8):1132\u201341.","journal-title":"Microb Drug Resist"},{"issue":"9","key":"374_CR35","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.1093\/jac\/dkaa183","volume":"75","author":"AG Stewart","year":"2020","unstructured":"Stewart AG, Harris PNA, Henderson A, et al. Oral cephalosporin and \u03b2-lactamase inhibitor combinations for ESBL-producing Enterobacteriaceae urinary tract infections. J Antimicrob Chemother. 2020;75(9):2384\u201393.","journal-title":"J Antimicrob Chemother"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-020-00374-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40121-020-00374-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-020-00374-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,12]],"date-time":"2021-03-12T06:41:16Z","timestamp":1615531276000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40121-020-00374-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,11]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["374"],"URL":"https:\/\/doi.org\/10.1007\/s40121-020-00374-7","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,11]]},"assertion":[{"value":"22 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}